Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma

Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma

David Aguiar-Bujanda, María Jesús Blanco-Sánchez, María Hernández-Sosa, Saray Galván-Ruíz, Samuel Hernández-Sarmiento Department of Medical Oncology, Hospital Universitario de Gran Canaria Doctor Negrí...

Full description

Bibliographic Details
Main Authors:	Aguiar-Bujanda D, Blanco-Sánchez MJ, Hernández-Sosa M, Galván-Ruíz S, Hernández-Sarmiento S
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-10-01
Series:	Cancer Management and Research
Online Access:	https://www.dovepress.com/critical-appraisal-of-rituximab-in-the-maintenance-treatment-of-advanc-peer-reviewed-article-CMAR

Similar Items

Maintenance rituximab in Veterans with follicular lymphoma
by: Ahmad S. Halwani, et al.
Published: (2020-10-01)

Rituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies
by: Vibor Milunović, et al.
Published: (2017-01-01)

Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma
Published: (2023-07-01)

Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma
by: Ru Li, et al.
Published: (2023-04-01)

PB2070: EFFICACY OF RITUXIMAB MAINTENANCE THERAPY IN ADVANCED-STAGE FOLLICULAR LYMPHOMA: A SINGLE-CENTER RETROSPECTIVE STUDY.
by: C. Amorós, et al.
Published: (2022-06-01)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
by: Vít Procházka, et al.
Published: (2020-07-01)

Pretreatment CT Texture Parameters as Predictive Biomarkers of Progression-Free Survival in Follicular Lymphoma Treated with Immunochemotherapy and Rituximab Maintenance
by: Carole Durot, et al.
Published: (2023-06-01)

Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma
by: Klaus Herfarth, et al.
Published: (2018-12-01)

Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape
by: Subramanian J, et al.
Published: (2017-04-01)

Cost-effectiveness Analysis of Rituximab Maintenance Treatment in Patients With Follicular Lymphoma who Respond to First Line Induction Therapy in Portugal
by: Susana Carvalho, et al.
Published: (2016-01-01)

Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation
by: D Papaioannou, et al.
Published: (2012-09-01)

Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma
by: A Boland, et al.
Published: (2009-09-01)

Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin’s lymphoma
by: Y Dundar, et al.
Published: (2009-06-01)

Human herpesvirus-6 pneumonitis in a patient with follicular lymphoma following immunochemotherapy with rituximab
by: Kuwahara-Ota S, et al.
Published: (2018-05-01)

Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma
by: Monika Enqvist, et al.
Published: (2019-09-01)

Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
by: Francisco‐Javier Peñalver, et al.
Published: (2019-11-01)

R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature
by: Vijay Patel, et al.
Published: (2009-03-01)

P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW-TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE III TRIAL, A LYSA STUDY.
by: G. Cartron, MD, PhD, et al.
Published: (2022-06-01)

Radiotherapy for early and advanced stages Follicular Lymphoma
by: Geovanne Pedro Mauro, et al.
Published: (2021-01-01)

The Role of Rituximab in Lymphomas
by: Bertrand Coiffier
Published: (2002-01-01)

Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non‐interventional study MabSCale
by: Jan Dürig, et al.
Published: (2023-02-01)

Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study
by: Judith Trotman, et al.
Published: (2023-03-01)

Serum immunoglobulin G as a discriminator of infection in follicular lymphoma patients undergoing chemotherapy with bendamustine in combination with rituximab
by: Akie Hirata, et al.
Published: (2022-12-01)

Severe Liver Damage and Nonallergic Bronchitis with Eosinophilia in a Patient with Follicular Lymphoma Treated with Bendamustine plus Rituximab
by: Tatsuro Jo, et al.
Published: (2014-07-01)

P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
by: L. H. Sehn, et al.
Published: (2022-06-01)

Follicular lymphoma
by: Ellen Leich, (Coordinating Author)
Published: (2019-06-01)

Follicular Lymphoma
by: İrfan Yavaşoğlu
Published: (2015-02-01)

Follicular lymphoma
by: Lali G. Babicheva, et al.
Published: (2020-06-01)

Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
by: Loretta J. Nastoupil, et al.
Published: (2022-05-01)

Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab
by: Cyrielle Rodier, et al.
Published: (2023-05-01)

Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era
by: Arushi Khurana, et al.
Published: (2021-07-01)

New Treatment Options in Advanced Stage Follicular Lymphoma
by: Kai Hübel, et al.
Published: (2018-12-01)

Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study
by: Sung Yong Oh, et al.
Published: (2019-10-01)

Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
by: Georg Hess, et al.
Published: (2020-06-01)

A rare face of follicular lymphoma: reverse variant of follicular lymphoma
by: Ninu Maskey, et al.
Published: (2020-04-01)

Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis.
by: Xuan Zhou, et al.
Published: (2017-01-01)

Follicular lymphoma genomics
by: Emil Kumar, et al.
Published: (2019-06-01)

Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
by: Michael Herold, et al.
Published: (2022-03-01)

RITUXIMAB INDUCED LUNG DISEASE IN A MANTLE CELL LYMPHOMA PATIENT RECEIVING MAINTENANCE: CASE PRESENTATION
by: Aslı Öztürkmen, et al.
Published: (2022-10-01)

The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study
by: Sara Galimberti, et al.
Published: (2017-06-01)